| EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. | lung, |
| Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. | lung, |
| EGFR and c-Met may interact in a synergistic manner in the oncogenesis and development of non-small cell lung cancer. Expressions were higher in smokers than in nonsmokers. | lung, |
| data identify NF-kappaB as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provide insight into the mechanisms by which tumour cells escape from oncogene dependence | lung, |
| FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. | lung, |
| Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas. | bladder, |
| Conversion from the oncogene addiction to drug addiction by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. | lung, |
| Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. | lung, |
| these results are the first to identify EGFR and MET-receptor-regulated miRNAs representing oncogenic signaling networks in NSCLCs. | lung, |
| CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be?. | lung, |
| Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. | lung, |
| Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. | sarcoma,breast, |
| these findings suggest that miR-542-5p may act as an important modulator of EGFR-mediated oncogenesis, with potential applications as a novel therapeutic target in lung cancer. | lung, |
| S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. | breast, |
| Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. | lung, |
| A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. | leukemia,HNSC, |
| EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. | lung, |
| EGFR signalling and oncogenic pathway signature in colorectal cancer. | colorectal, |
| Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. | breast, |
| P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. | breast, |